Galapagos Knocked By Knee Osteoarthritis Fail
Servier-Partnered Drug Shows No Activity in Phase II
Still reeling from the FDA rejection of its JAK inhibitor filgotinib for rheumatoid arthritis, the Belgium-headquartered biotech's ADAMTS-5 inhibitor developed with France's Servier is sunk after failing to significantly reduce cartilage loss compared with placebo in an OA trial.
